Olfactory mucosa mesenchymal stem cells alleviate pulmonary fibrosis via the immunomodulation and reduction of inflammation

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Background

Pulmonary fibrosis (PF) is a progressive fibrosing interstitial pneumonia that leads to respiratory failure and other complications, which is ultimately fatal. Mesenchymal stem cells (MSCs) transplant is a promising strategy to solve this problem, while the procurement of MSCs from the patient for autotransplant remains a challenge.

Methods

Here, we presented olfactory mucosa mesenchymal stem cells (OM-MSCs) from mouse turbinate and determined the preventing efficacy of allotransplant for PF. We demonstrated the antiinflammation and immunomodulatory effects of OM-MSCs. Flow cytometric analysis was used to verify the effect of OM-MSCs on monocyte-derived macrophage populations in the lung.

Results

Administration of OM-MSCs reduces inflammation, attenuates the matrix metallopeptidase 13 (MMP13) expression level and restores the bleomycin (BLM)-induced pulmonary fibrosis by assessing the architecture of lung, collagen type I; (COL1A1), actin alpha 2, smooth muscle, aorta (ACTA2/α-SMA) and hydroxyproline. This therapeutic effect of OM-MSCs was related to the increase in the ratio of nonclassical monocytes to proinflammatory monocytes in the lung.

Conclusions

This study suggests that transplant of OM-MSCs represents an effective and safe treatment for PF.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12890-023-02834-5.

Related collections

Most cited references 31

Record: found
Abstract: found
Article: not found

Idiopathic pulmonary fibrosis.

Luca Richeldi, Harold Collard, Mark G. Jones (2017)

Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease. Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is destroyed, which leads to decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death. In less than a decade, understanding of the pathogenesis and management of this disease has been transformed, and two disease-modifying therapies have been approved, worldwide. In this Seminar, we summarise the presentation, pathophysiology, diagnosis, and treatment options available for patients with idiopathic pulmonary fibrosis. This disease has improved understanding of the mechanisms of lung fibrosis, and offers hope that similar approaches will transform the management of patients with other progressive fibrotic lung diseases.

0 comments Cited 708 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Peter George, Athol Wells, R. Jenkins (2020)

Summary In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the end of April, 2020, over 3 million people had been confirmed infected, with over 1 million in the USA alone, and over 215 000 deaths. The symptoms associated with COVID-19 are diverse, ranging from mild upper respiratory tract symptoms to severe acute respiratory distress syndrome. The major risk factors for severe COVID-19 are shared with idiopathic pulmonary fibrosis (IPF), namely increasing age, male sex, and comorbidities such as hypertension and diabetes. However, the role of antifibrotic therapy in patients with IPF who contract SARS-CoV-2 infection, and the scientific rationale for their continuation or cessation, is poorly defined. Furthermore, several licensed and potential antifibrotic compounds have been assessed in models of acute lung injury and viral pneumonia. Data from previous coronavirus infections such as severe acute respiratory syndrome and Middle East respiratory syndrome, as well as emerging data from the COVID-19 pandemic, suggest there could be substantial fibrotic consequences following SARS-CoV-2 infection. Antifibrotic therapies that are available or in development could have value in preventing severe COVID-19 in patients with IPF, have the potential to treat severe COVID-19 in patients without IPF, and might have a role in preventing fibrosis after SARS-CoV-2 infection.

0 comments Cited 521 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Simple method of estimating severity of pulmonary fibrosis on a numerical scale.

T. Ashcroft, J. Simpson, V. Timbrell (1988)

A continuous numerical scale for determining the degree of fibrosis in lung specimens was devised for correlation with other pulmonary variables such as lung function tests or mineral burden. Grading was scored on a scale from 0 to 8, using the average of microscope field scores. The system allows fibrosis to be measured in small samples of tissue (1 cm) which can provide a detailed description of the changes in a lung, currently not possible with most existing methods.

0 comments Cited 519 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Hui Xie: huixie@csu.edu.cn

Zheng-Zhao Liu: liuzhengzhao@gdmu.edu.cn

Journal

Journal ID (nlm-ta): BMC Pulm Med

Journal ID (iso-abbrev): BMC Pulm Med

Title: BMC Pulmonary Medicine

Publisher: BioMed Central (London )

ISSN (Electronic): 1471-2466

Publication date (Electronic): 5 January 2024

Publication date PMC-release: 5 January 2024

Publication date Collection: 2024

Volume: 24

Electronic Location Identifier: 14

Affiliations

[1 ]Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-Communicable Diseases, Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City, Institute of Nephrology, Affiliated Hospital of Guangdong Medical University, ( https://ror.org/04k5rxe29) 524001 Zhanjiang, Guangdong China

[2 ]GRID grid.216417.7, ISNI 0000 0001 0379 7164, Department of Sports Medicine, Xiangya Hospital, , Central South University, ; 410008 Changsha, Hunan China

[3 ]GRID grid.216417.7, ISNI 0000 0001 0379 7164, Movement System Injury and Repair Research Center, Xiangya Hospital, , Central South University, ; 410008 Changsha, Hunan China

[4 ]Department of Neurosurgery, Second affiliated Hospital of Hunan Normal University (921 Hospital of PLA), ( https://ror.org/053w1zy07) 410081 Changsha, Hunan China

Article

Publisher ID: 2834

DOI: 10.1186/s12890-023-02834-5

PMC ID: 10768423

PubMed ID: 38178092

SO-VID: db4626bf-f080-4fc4-b4c1-81125cbb0a05

License:

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

History

Date received : 16 November 2023

Date accepted : 28 December 2023

Funding

Funded by: Fundamental Research Funds for Central Universities of the Central South University

Award ID: 2020zzts859

Funded by: National Natural Science Foundation of China

Award ID: 82172502

Custom metadata

ScienceOpen disciplines: Respiratory medicine

Keywords: olfactory mucosa mesenchymal stem cells,pulmonary fibrosis,monocyte,inflammation,collagen

Data availability:

ScienceOpen disciplines: Respiratory medicine

Keywords: olfactory mucosa mesenchymal stem cells, pulmonary fibrosis, monocyte, inflammation, collagen

Olfactory mucosa mesenchymal stem cells alleviate pulmonary fibrosis via the immunomodulation and reduction of inflammation

Read this article at

Abstract

Background

Methods

Results

Conclusions

Supplementary Information

Related collections

Biomarkers for Inflammatory Lung Disease

Most cited references 31

Idiopathic pulmonary fibrosis.

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Simple method of estimating severity of pulmonary fibrosis on a numerical scale.

Author and article information

Contributors

Journal

Affiliations

Article

History

Funding

Categories

Custom metadata

Comments

Comment on this article

Similar content 409

Most referenced authors 457